TY - JOUR
T1 - Outcomes of cataract surgery in diabetic patients
T2 - Results of the pan american collaborative retina study group
AU - Gallego-Pinazo, Roberto
AU - Dolz-Marco, Rosa
AU - Berrocal, M. H.
AU - Wu, Lihteh
AU - Maia, Mauricio
AU - Serrano, Martín
AU - Alezzandrini, Arturo
AU - Arévalo, J. Fernando
AU - Díaz-Llopis, Manuel
AU - Kozak, I.
AU - Gupta, V.
AU - Al-Rashaed, S.
AU - Al-Kahtani, E.
AU - Lasave, A. F.
AU - Farah, M.
AU - Penha, F. M.
AU - Rodrigues, E. B.
AU - Morales-Canton, V.
AU - Fromow-Guerra, J.
AU - Guerrero-Naranjo, J. L.
AU - Dalma-Weiszhausz, J.
AU - Martinez-Castellanos, M. A.
AU - Quiroz-Mercado, H.
AU - Velez-Montoya, R.
AU - Rodriguez, F. J.
AU - Gomez, F. E.
AU - Brieke, A. C.
AU - Berrocal, M. H.
AU - Cruz-Villegas, V.
AU - Graue-Wiechers, F.
AU - Lozano-Rechy, D.
AU - Ariza-Camacho, E.
AU - Roca, J. A.
AU - Chico, R. G.
AU - Saravia, M. J.
AU - Schlaen, A.
AU - Lupinacci, A.
AU - Gabin, M. N.
AU - Avila, M.
AU - Carla, L.
AU - Cardillo, J.
AU - Carpentier, C.
AU - Verdaguer, T. J.
AU - Verdaguer, D. J.I.
AU - Sepúlveda, G.
AU - Garcia, B.
AU - Bregliano, G.
AU - Alvira, G.
AU - Flor, P.
AU - Jaramillo, F.
PY - 2014
Y1 - 2014
N2 - Purpose: This study was designed to evaluate the visual and anatomical outcomes after cataract surgery in diabetic patients with different intraoperative therapeutic strategies. Methods: The research design comprised of a multicentric, retrospective, interventional study conducted at 6 centers in Argentina, Brazil, Costa Rica, Puerto Rico, Spain, and Venezuela. We included 138 diabetic patients with at least 6-month follow-up following phacoemulsification and intraocular lens implantation. Best-corrected visual acuity (BCVA) and central subfield thickness were collected at baseline and at 1-, 2-, 3-, and 6-month follow-up. Of these, 42 cases were not treated with any intraoperative coadjuvant medication (Group 1), 59 patients received intraoperative bevacizumab (Group 2) and 37 patients received intraoperative triamcinolone (4 mg/0.1 ml) (Group 3). Results: The mean logMAR [± standard deviation (SD)] BCVA improved from 0.82 (± 0.43) at baseline, to 0.14 (± 0.23) at 6-month follow-up (p<0.001) in Group 1; from 0.80 (± 0.48) to 0.54 (± 0.45) (p<0.001) in Group 2; and from 1.0 (± 0.40) to 0.46 (± 0.34) (p<0.001) in Group 3. The mean central subfield thickness increased from 263.57 μm (± 35.7) at baseline to 274.57 μm (± 48.7) at 6-month follow-up (p=0.088) in Group 1; from 316.02 μm (± 100.4) to 339.56 μm (± 145.3) (p=0.184) in Group 2; and from 259.18 μm (± 97.9) to 282.21 μm (± 87.24) (p=0.044) in Group 3. Conclusions: Diabetic patients may significantly benefit from cataract surgery. This study provides evidence to support the use of intravitreal triamcinolone or bevacizumab at the time of cataract surgery in cases with pre-existent diabetic macular edema or moderate-severe non-proliferative diabetic retinopathy.
AB - Purpose: This study was designed to evaluate the visual and anatomical outcomes after cataract surgery in diabetic patients with different intraoperative therapeutic strategies. Methods: The research design comprised of a multicentric, retrospective, interventional study conducted at 6 centers in Argentina, Brazil, Costa Rica, Puerto Rico, Spain, and Venezuela. We included 138 diabetic patients with at least 6-month follow-up following phacoemulsification and intraocular lens implantation. Best-corrected visual acuity (BCVA) and central subfield thickness were collected at baseline and at 1-, 2-, 3-, and 6-month follow-up. Of these, 42 cases were not treated with any intraoperative coadjuvant medication (Group 1), 59 patients received intraoperative bevacizumab (Group 2) and 37 patients received intraoperative triamcinolone (4 mg/0.1 ml) (Group 3). Results: The mean logMAR [± standard deviation (SD)] BCVA improved from 0.82 (± 0.43) at baseline, to 0.14 (± 0.23) at 6-month follow-up (p<0.001) in Group 1; from 0.80 (± 0.48) to 0.54 (± 0.45) (p<0.001) in Group 2; and from 1.0 (± 0.40) to 0.46 (± 0.34) (p<0.001) in Group 3. The mean central subfield thickness increased from 263.57 μm (± 35.7) at baseline to 274.57 μm (± 48.7) at 6-month follow-up (p=0.088) in Group 1; from 316.02 μm (± 100.4) to 339.56 μm (± 145.3) (p=0.184) in Group 2; and from 259.18 μm (± 97.9) to 282.21 μm (± 87.24) (p=0.044) in Group 3. Conclusions: Diabetic patients may significantly benefit from cataract surgery. This study provides evidence to support the use of intravitreal triamcinolone or bevacizumab at the time of cataract surgery in cases with pre-existent diabetic macular edema or moderate-severe non-proliferative diabetic retinopathy.
UR - http://www.scopus.com/inward/record.url?scp=84922059273&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84922059273&partnerID=8YFLogxK
U2 - 10.5935/0004-2749.20140089
DO - 10.5935/0004-2749.20140089
M3 - Article
C2 - 25627180
AN - SCOPUS:84922059273
SN - 0004-2749
VL - 77
SP - 355
EP - 359
JO - Arquivos Brasileiros de Oftalmologia
JF - Arquivos Brasileiros de Oftalmologia
IS - 6
ER -
